Navigation Links
Watson Confirms Daytrana(R) Patent Challenge
Date:10/14/2011

PARSIPPANY, N.J., Oct. 14, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Transdermal System, 10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs, and 30 mg/9 hrs.  Watson's Methylphenidate Transdermal System products are generic versions of Noven Pharmaceuticals, Inc.'s Daytrana(R).  Daytrana(R) is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Noven filed suit against Watson on October 13, 2011 in the United States District Court of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 6,210,705 and 6,348,211.  Noven's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date Noven received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic versions of Daytrana(R)  and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

For the twelve months ending July 31, 2011, Daytrana(R) had total U.S. sales of over $87 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010 and Watson's quarterly report on Form 10-Q for the period ended June 30, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Daytrana(R) is a registered trademark of Noven Therapeutics, LLC.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
2. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
3. Watson Confirms EMBEDA(R) Patent Challenge
4. Watson Launches Generic FEMCON(R) Fe
5. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
6. Watson to Present at the Jefferies 2011 Global Healthcare Conference
7. Watson Confirms Amphastar Patent Lawsuit
8. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
9. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
10. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
11. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... 2017  Researchers from DRUGSCAN ® and INC ... a live, complimentary webinar titled, "Untangling methods to tamper ... real world" on Wednesday June 28, 2017 from 12:00 ... webinar will feature interviews with recreational and dependent prescription ... techniques abusers use to prepare opioid tablets for routes ...
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom of ... technical specifications . , 2017 has seen an explosion of token launches by blockchain ... will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, “We ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and Widex ... Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate hearing ... today’s savvy consumer, and the latest in hearing technology. At the event, EarQ ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR ... an upcoming case studies guidebook. This guidebook offers an excellent branding and exposure ... include articles, case studies and how-to’s that fall into the following categories:, ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Hammer Strength, ... Association (NBSCA) have named Javair Gillett of the Houston Rockets the NBSCA Strength & ... the award is decided by NBSCA members who vote to select the coach who ...
(Date:6/27/2017)... ... June 27, 2017 , ... Children’s National Health System ... rankings, with its Neonatology program ranking #1 out of more than 1500 neonatal ... to the coveted Honor Roll, a distinction given to the top performing children’s hospitals ...
Breaking Medicine News(10 mins):